solute carrier family 35 member F1Genealiases: C6orf169 · dJ230I3.1
Q-omics provides the consensus-scored SLC35F1 profile across patient tissues and cancer cell-line models. SLC35F1 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SLC35F1 is differentially expressed in 14, with the highest sampling consensus in COAD. Additionally, SLC35F1 RNA expression shows 15,983 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, COAD, and TGCT as cancer lineages where SLC35F1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLC35F1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLC35F1 survival associations across molecular data types. SLC35F1 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (3) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLC35F1 RNA expression–survival associations across cancer types. High SLC35F1 expression shows unfavorable associations in ACC, KIRP, STAD and LUAD, but favorable associations in KIRC and SKCM. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SLC35F1 RNA expression.
This table summarizes SLC35F1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for SLC35F1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLC35F1 shows lower tumor expression in COAD, KICH, UCEC, BRCA and HNSC and higher tumor expression in LIHC. The COAD box plot shows higher SLC35F1 RNA expression in normal versus tumor tissue (log2 FC = −0.877, t-test p < 0.001).
This table shows molecular features associated with SLC35F1 in patient tissues and cancer cell lines. In patient samples, SLC35F1 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, SLC35F1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in BONE and LARGE_INTESTINE.
